Zivo Bioscience Joins Russell Microcap® Index

BLOOMFIELD HILLS, Mich.–(BUSINESS WIRE)–ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual … [Read more…]

Ambys Medicines Announces Formation of Clinical and Scientific Advisory Boards with Leading Liver Disease and Cell and Gene Therapy Experts

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies. The clinical advisory board provides guidance on advancing Ambys’s lead … [Read more…]

Walgreens Honors Veterans, Active Duty Military and Families with Weekend Discount in Honor of Independence Day Friday, July 1 through Monday, July 4

DEERFIELD, Ill.–(BUSINESS WIRE)–To honor the service and sacrifices of Americans who served in the armed forces, Walgreens is offering a weekend Independence Day discount to all veterans, active duty military personnel and their immediate family members, including the families of those who lost their lives in service to their country. Beginning July 1 through July … [Read more…]

Valtruis Brings Advanced Healthcare Data Analytics Capabilities Into Its Portfolio With Ursa Health Partnership

NEW YORK–(BUSINESS WIRE)–#valuebasedcare—Valtruis, a WCAS company, has entered a strategic partnership with Ursa Health, a healthcare data analytics company that brings a paradigm-breaking approach to how healthcare organizations use their data to learn, make decisions, and innovate. Valtruis portfolio companies Cricket Health and Wayspring are already experiencing quantifiable advances in their data analysis and management … [Read more…]

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds … [Read more…]

Drips Receives Top Workplaces 2022 Honor

Fast-Growing Akron-Based Tech Firm Recognized as a Top Workplace for Employees AKRON, Ohio–(BUSINESS WIRE)–#ai–Drips announced today it has been awarded a Northeast Ohio Top Workplaces 2022 honor by cleveland.com and The Plain Dealer. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC. The … [Read more…]

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high … [Read more…]

BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products

OTTAWA, Ontario–(BUSINESS WIRE)–$BWXT–BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225). Today’s announcement follows the agreement reached by the two companies in September 2021. Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT … [Read more…]

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

− Fibrosis regression observed in 58% (7 of 12) of patients receiving 200 mg fazirsiran − Median reduction of 83% of Z-AAT accumulation in the liver − Reduction of 69% in histologic globule burden − Substantial and sustained improvements in clinically relevant biomarkers of liver health OSAKA, Japan & PASADENA, Calif.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and … [Read more…]

Global Molecular Diagnostics Partnering Terms and Agreements Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Molecular Diagnostics Partnering Terms and Agreements 2015 to 2022” report has been added to ResearchAndMarkets.com’s offering. Key benefits In-depth understanding of Molecular Diagnostics deal trends since 2015 Access to headline, upfront, milestone and royalty data Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies Identify most active Molecular … [Read more…]